GLUE Stock GLUE is expected to report earnings to fall -1.48% to -59 cents per share on May 09

A.I.dvisor
at Tickeron.com
05/08/24
Loading...
GLUE - Monte Rosa Therapeutics
Monte Rosa Therapeutics Earnings Graph
Q1'24
Est.
$-0.59
Q4'23
Missed
by $0.19
Q3'23
Beat
by $0.02
Q2'23
Missed
by $0.01
Q1'23
Beat
by $0.03
The last earnings report on December 31 showed earnings per share of -58 cents, missing the estimate of -39 cents. P/B Ratio (1.595) is normal, around the industry mean (10.346). P/E Ratio (0.000) is within average values for comparable stocks, (113.451). GLUE's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.447). GLUE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (0.000) is also within normal values, averaging (231.135). With 189.93K shares outstanding, the current market capitalization sits at 285.85M.
View a ticker or compare two or three
GLUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
321 Harrison Avenue
Phone
+1 617 949-2643
Employees
133
Web
https://www.monterosatx.com